InSite Vision Inc., of Alameda, Calif., completed patient enrollment in the Phase III DOUBle (Dual Ophthalmic agents Used in Blepharitis) trial of AzaSite Plus (ISV-502) and DexaSite (ISV-305) in blepharitis. The study enrolled more than 900 patients with moderate to severe blepharitis in a four-arm trial designed to evaluate the efficacy and safety of both product candidates simultaneously.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST